- 01Patrys forms CAC to guide RLS-2202 delirium injectable
- 02Chair: Dr Johnny Iliff leads strategy.
- 03US Prof John W Devlin and EU Prof Mark van den Boogaard join
Patrys (ASX: PAB) has established a clinical advisory committee (CAC) to guide the development of quetiapine injectable formulation RLS-2202 to treat delirium in acute-care settings.
The committee brings together acute and critical care expertise from Australia, the US, and Europe, including internationally recognised specialists in delirium research, prevention, detection and management, as well as acute and critical care medicine, clinical trial design and guidelines, and health system adoption.
This combination of perspectives is intended to help Patrys design future RLS-2202 studies that are clinically robust, practical to conduct in acute-care settings, and informed by clinical practice across the company’s key target markets.
Establishment of the committee aligns with Patrys’ progress on a Phase 1 trial of RLS-2202 in healthy volunteers and subsequent clinical evaluation in patients with delirium.
Committee Chair Named
The CAC will be chaired by senior critical care clinician Dr Johnny Iliff, who works in emergency care at Royal Perth Hospital and St John of God Hospital (Murdoch).
Dr Iliff is also an aeromedical consultant for the Royal Flying Doctor Service, with a special interest in trauma care and blood management.
He will be instrumental in shaping Patrys’ clinical development strategy, ensuring that recommendations for the RLS-2202 program are feasible, safe, and aligned with how delirium is prevented, detected, and managed in critically ill patients within acute-care settings.
His role will extend across Patrys’ broader pipeline, providing clinical input as further development opportunities are identified and progressed.
US-Based Specialist
Dr Iliff will be joined by internationally recognised delerium specialist Professor John W Devlin, who is based in Massachusetts as a professor of pharmacy at Northeastern University.
Professor Devlin holds additional roles as an associate scientist in pulmonary and critical care medicine at Brigham and Women’s Hospital, and an instructor of medicine at Harvard Medical School.
He chaired the Society of Critical Care Medicine’s 2018 international pain, agitation/sedation, delirium, immobility, and sleep disruption (PADIS) guidelines, considered to be a cornerstone framework for ICU delirium management, and has also helped lead the implementation of PADIS recommendations across US health systems.
A past president of the American Delirium Society, Professor Devlin serves on an American Thoracic Society taskforce setting research priorities for ICU sleep, sits on the editorial boards of Critical Care Medicine and Pharmacotherapy, and co-directs the government-funded Network for Investigation of Delirium: Unifying Scientists.
European Representative
European representation on the CAC will come from Professor Mark van den Boogaard, who works in acute nursing science at the Department of Intensive Care at Radboud University Medical Centre in the Netherlands.
He is an associate editor of Intensive and Critical Care Nursing, as well as an unpaid board member of the National Intensive Care Evaluation Foundation, and an advisory board member of NIDUS.
Professor van den Boogaard developed the widely used (E-)PRE-DELIRIC delirium prediction model and co-leads a multi-centre prospective longitudinal MONITOR-IC cohort study following long-term outcomes in over 20,000 ICU survivors across eight Dutch hospitals.
An executive board member of the European Delirium Association, he has contributed to US and Dutch ICU clinical guidelines, providing significant experience across delirium research, intensive care clinical practice, and the development and implementation of clinical guidelines.
His background provides the CAC with a European perspective on intensive-care practice, delirium research, clinical trial considerations, and the implementation of evidence-based care.
Key Collective Expretise
Patrys chief executive officer Dr Samantha South welcomed Dr Iliff, Professor Devlin, and Professor van den Boogaard to the CAC.
“Their collective expertise will be instrumental as we advance RLS-2202 through clinical development, helping ensure our trials are designed and executed to the highest scientific and clinical standards,” she said.
“These appointments reflect a continued focus on strengthening our clinical and academic leadership in critical care, delirium research and education.
“Together, their expertise will deepen our engagement with the international ICU and delirium community and support our work to develop RLS-2202 as a potential treatment for delirium in acute-care settings.”
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.